Large Cap BSE: 532488 NSE: DIVISLAB
2.75 (0.07%)
  • Advice
  • Hold
As on 07 October, 2022 | 17:57

Divi's Laboratories Share Price

Divi's Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume


Start SIP

Divi's Laboratories Share Returns

  • Over 1 Month 4.19%
  • Over 3 Month 2.5%
  • Over 6 Month -14.84%
  • Over 1 Year -27.27%

Divi's Laboratories Key Statistics

P/E Ratio 31.9
PEG Ratio 0.6
Market Cap Cr 99,172
Price to Book Ratio 8.5
EPS 111.1
Dividend 0.8
Relative Strength Index 57.89
Money Flow Index 73.44
MACD Signal 8.08
Average True Range 77.31

Divi's Laboratories Investment Rating

  • Master Rating:
  • Divis Laboratories (Nse) has an operating revenue of Rs. 9,253.71 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 41% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 115 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Divi's Laboratories Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 2,2042,4952,4671,9681,9501,718
Operating Expenses Qtr Cr 1,3661,3991,3671,1491,0991,019
Operating Profit Qtr Cr 8381,0961,100819851699
Depreciation Qtr Cr 838180777370
Interest Qtr Cr 000000
Tax Qtr Cr 152183129154262164
Net Profit Qtr Cr 692883907606552488

Divi's Laboratories Technicals


Current Price
2.75 (0.07%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 3675.75
  • 50 Day
  • 3686.01
  • 100 Day
  • 3773.93
  • 200 Day
  • 4035.66
  • 20 Day
  • 3655.23
  • 50 Day
  • 3693.29
  • 100 Day
  • 3689.01
  • 200 Day
  • 4034.36

Divi's Laboratories Resistance and Support

First Resistance 3788.72
Second Resistance 3844.44
Third Resistance 3882.27
RSI 57.6
MFI 69.92
MACD Single Line 4.24
MACD 21.67
First Resistance 3695.17
Second Resistance 3657.34
Third Resistance 3601.62

Divi's Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 363,630 17,126,973 47.1
Week 419,270 19,567,331 46.67
1 Month 459,365 24,043,157 52.34
6 Month 553,939 26,539,227 47.91

Divi's Laboratories Result Highlights

Divi's Laboratories Synopsis

NSE-Medical-Generic Drugs

Divi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 8879.82 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2022. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
Market Cap 99,126
Sales 9,134
Shares in Float 12.74
No of funds 791
Yield 0.8
Book Value 8.48
U/D Vol ratio 0.8
LTDebt / Equity
Alpha -0.11
Beta 0.73

Divi's Laboratories

Owner NameJun-22Mar-22Dec-21
Promoters 51.94%51.94%51.95%
Mutual Funds 13.85%13.68%13.35%
Foreign Portfolio Investors 16.52%18.45%19.3%
Financial Institutions/ Banks 0.09%0.05%0.05%
Individual Investors 9.53%9.27%9.01%
Others 8.07%6.61%6.34%

Divi's Laboratories Management

Name Designation
Dr. Ramesh B V Nimmagadda Non Exe.Chairman&Ind.Director
Dr. Murali K Divi Managing Director
Dr. Kiran S Divi WholeTime Director & CEO
Ms. Nilima Prasad Divi Whole Time Director
Mr. Madhusudana Rao Divi Whole Time Director
Mr. N V Ramana Executive Director
Mr. K V K Seshavataram Independent Director
Dr. G Suresh Kumar Independent Director
Mr. R Ranga Rao Independent Director
Prof. Sunaina Singh Independent Director
Dr. S Ganapaty Independent Director
Mr. K V Chowdary Independent Director

Divi's Laboratories Forecast

Price Estimates


Other Analyst Rating

Divi's Laboratories Corporate Action

Date Purpose Remarks
2022-08-12 Quarterly Results
2022-05-23 Audited Results & Dividend
2022-02-11 Quarterly Results (Revised) per share(500%)Dividend
2021-11-06 Quarterly Results
2021-08-07 Quarterly Results
Date Purpose Remarks
2022-08-12 FINAL Rs.30.00 per share(1500%)Dividend

Divi's Laboratories MF Shareholding

Name Amount(cr)
SBI Nifty 50 ETF 143463
SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl 55268
ICICI Prudential Balanced Advantage Fund Growth 42930
UTI Nifty 50 Exchange Traded Fund 37189
Axis Bluechip Fund Growth 36980

About Company

Established in 1990, the Indian multinational pharmaceuticals company Divis Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs)including generic APIs, Nutraceutical Ingredients, and Custom Synthesis of the APIs providing high-quality products to over 95 countries. It is headquartered in Hyderabad, Telangana, India.

Divis Laboratories is among the world's leading manufacturers of generic APIs, offering a competitive advantage over the entire life cycle of the products. Competent in handling high-potency, high-energy reactions to fulfil the unmet needs of the big pharma customers, Divis Laboratories is the second most valuable pharmaceutical firm in India by market value.


In 1990, Divis Laboratories was founded as Divis Research Centre. Initially, the company began developing commercial techniques for the production of APIs and intermediates. In 1994, Divis Research Centre rebranded as Divis Laboratories Limited to indicate its entry into the API and intermediates manufacturing industry.

1997: The United Kingdom's SGS–Yarsley certifies Divis Laboratories as ISO–9002 compliant.
1999: The European Directorate issues a Certificate of Suitability (CoS) for the Naproxen manufactured by Divis Laboratories.
2001: London's BVQI grants Divis OHSAS–18001 Certification (for its Occupational Health and Safety Management Systems).
2003: Divis inaugurates a new research centre dubbed "DRC–Vizag".
2003: Went for IPO and was listed on the BSE, NSE, and HSE stock markets.
2007: Set up Nutraceuticals facility at Unit 2
2008: The third US-FDA examination of Choutuppal(Unit-1).
2008: The Visakhapatnam(Unit–2) is inspected by the KFDA.
2010: Letter of approval received by Divis Laboratories for the establishment and development of a new pharmaceutical ingredient manufacturing unit in SEZ at Visakhapatnam.
2016: First Anvisa (Brazil) inspection
2020: 8th USFDA inspection at unit 2.

Shareholding Pattern

Up until March 2022, the Promoters of Divis Laboratories held 51.94% of the business's shares, FII/FPI held around 18.45%, and mutual funds increased their holdings to 13.68 %, and institutional investors held 36.77% of the company. In addition, public holdings account for 11.3% of the company's equity. The company's equity is held by retail and other investors to the tune of 4.6%.

Corporate Social Responsibility

Corporate Social Responsibility at Divis Laboratories consists of social programs, community service, and environmental impact awareness. Some key initiatives are mentioned below.

Child Empowerment Initiatives- 

Promoting Education
Preventive Healthcare
Empowering Women
Safe Drinking water
Swaach Bharat

Healthcare Initiatives-

Free Eye and Dental care Camps
ORT training and pulse polio campaigns
Incentives for Family Planning and awareness campaigns on HIV/ Aids, epidemics and malaria

Initiatives for Development of Village-

Laying of CC Roads in Villages
Construction of underground Drainages in Villages
Construction of Overhead Tanks
Laying of Gravel Roads from villages to Agricultural Fields
Facilitate Street lights in Villages


Top Line

Over the last 5 years, the audited financial statements were INR 3928 crores in 2018, INR 5036.24 crore in 2019, INR 5500 crore in 2020, INR 6861 crore in 2021, and INR 8991 crore in 2022.

Bottom Line

The profit recorded has grown exponentially from INR 1219 crore to INR 3676 crore in 5 yrs. The highest growth can be shown in the years 2021-2022 which is around INR 1000 crores. This is due to a substantial rise in revenue and a decrease in selling, general, and administrative costs.

Net Worth

The net worth of Divis Laboratory as calculated till 2022 is INR 11691.35 crore. It has grown by a whopping INR 5668.59 crore over the last 5 yrs.


Divi's Laboratories FAQs

What is Share Price of Divi's Laboratories ?

Divi's Laboratories share price is ₹3735 As on 07 October, 2022 | 17:43

What is the Market Cap of Divi's Laboratories ?

The Market Cap of Divi's Laboratories is ₹99172.4 Cr As on 07 October, 2022 | 17:43

What is the P/E ratio of Divi's Laboratories ?

The P/E ratio of Divi's Laboratories is 31.9 As on 07 October, 2022 | 17:43

What is the PB ratio of Divi's Laboratories ?

The PB ratio of Divi's Laboratories is 8.5 As on 07 October, 2022 | 17:43

What does Divis Laboratories do?

Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.

Is Divis Laboratories good for the long term?

Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.

Is Divis Laboratories debt-free?

Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

Who is the owner of Divis Laboratories?

Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).

How to buy Divis Laboratory?

You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.